Gene therapy for hemophilia from Pfizer and Sangamo shows promise

Gene therapy for hemophilia from Pfizer and Sangamo shows promise

STAT Plus: Experimental gene therapy for hemophilia, developed by Pfizer and Sangamo, shows early promise

By DAMIAN GARDE

ADOBE

The new data are early, but point to a possible future in which patients might have a handful of curative options for the rare bleeding disorder.

READ MORE